EARNEST PARTNERS LLC - NEKTAR THERAPEUTICS ownership

NEKTAR THERAPEUTICS's ticker is NKTR and the CUSIP is 640268108. A total of 284 filers reported holding NEKTAR THERAPEUTICS in Q4 2019. The put-call ratio across all filers is 1.03 and the average weighting 0.1%.

Quarter-by-quarter ownership
EARNEST PARTNERS LLC ownership history of NEKTAR THERAPEUTICS
ValueSharesWeighting
Q3 2023$49
+2.1%
830.0%0.00%
Q2 2023$48
-17.2%
830.0%0.00%
Q1 2023$58
-69.1%
830.0%0.00%
Q4 2022$188830.0%0.00%
Q3 2022$0830.0%0.00%
Q2 2022$0830.0%0.00%
Q1 2022$0
-100.0%
830.0%0.00%
Q4 2021$1,0000.0%830.0%0.00%
Q3 2021$1,0000.0%830.0%0.00%
Q2 2021$1,000
-50.0%
830.0%0.00%
Q1 2021$2,000
+100.0%
830.0%0.00%
Q4 2020$1,0000.0%830.0%0.00%
Q3 2020$1,000
-50.0%
830.0%0.00%
Q2 2020$2,000
+100.0%
830.0%0.00%
Q1 2020$1,000
-50.0%
830.0%0.00%
Q4 2019$2,0000.0%830.0%0.00%
Q3 2019$2,000
-33.3%
830.0%0.00%
Q2 2019$3,0000.0%830.0%0.00%
Q1 2019$3,0000.0%830.0%0.00%
Q4 2018$3,000
-40.0%
830.0%0.00%
Q3 2018$5,000
+25.0%
830.0%0.00%
Q2 2018$4,000830.00%
Other shareholders
NEKTAR THERAPEUTICS shareholders Q4 2019
NameSharesValueWeighting ↓
Camber Capital Management LP 2,000,000$67,200,0003.35%
First Light Asset Management, LLC 763,403$25,650,0003.33%
BRIDGER MANAGEMENT, LLC 1,238,489$41,613,0003.29%
Rhenman & Partners Asset Management AB 734,445$24,677,0002.89%
BB BIOTECH AG 2,020,676$67,895,0001.71%
Gs Investments, Inc. 54,200$1,821,120,0001.43%
Artal Group S.A. 900,000$30,240,0001.24%
Cormorant Asset Management, LP 500,000$16,800,0001.14%
TOBAM 640,547$21,522,0001.09%
Bellevue Group AG 430,026$14,449,0000.80%
View complete list of NEKTAR THERAPEUTICS shareholders